Hana Biosciences leukemia drug Talotrexin gets orphan drug designation

By Elaine Rigoli

Tampa, Fla., May 22 - Hana Biosciences announced that the Food and Drug Administration has granted orphan drug designation for Talotrexin (PT-523) in patients with acute lymphoblastic leukemia.

Talotrexin, a novel nonpolyglutamatable antifolate drug, is being evaluated in a phase 1/2 multicenter clinical trial in patients with relapsed or refractory acute lymphoblastic leukemia, according to a news release.

Hana Biosciences is a South San Francisco, Calif.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.